Tekla Life Sciences Investors

Tekla Life Sciences Investors

HQL·NYSE

$16.93

-1.5%
Financial ServicesAsset Management

Tekla Life Sciences Investors is a closed-ended equity mutual fund launched and managed by Tekla Capital Management LLC. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries. The fund primarily invests in growth stocks of small cap companies. It employs fundamental analysis with a focus on factors such as market position for services or products, experience of business management, technological expertise, and the ability either to generate funds internally to finance growth or to secure outside sources of capital to create its portfolio. The fund benchmarks the performance of its portfolio against the NASDAQ Biotech Index and the S&P 500 Index. It was formerly known as H&Q Life Sciences Investors fund. Tekla Life Sciences Investors was formed on February 20, 1992 and is domiciled in the United States.

At a Glance

Live Snapshot
Market Cap$514.81M
EPS2.9600
P/E Ratio5.72
Earnings Date06/24/2025

hql

EPS

Last Annual Value

2.96

3-Year CAGR

40%

5-Year CAGR

-11%

10-Year CAGR

4%

Tekla Life Sciences Investors

Tekla Life Sciences Investors Competitors Analysis of EPS

HQL · NYSE
CompanyEPS
CAGR 3Y
CAGR 5Y
CAGR 10Y
2.96
55.3%2.2%11.5% 
0.93
-26.4%-20.6%-6.5%
1.37
-9.0%-12.0%-0.1%
-0.39
N/AN/AN/A
0.11
N/AN/AN/A
-1.05
N/AN/AN/A
7.24
3.7%7.9%8.4%
0.50
N/A-27.5%6.8%
-1.05
N/AN/AN/A
0.00
N/AN/AN/A
2.56
3.8%-12.8%10.1%
Tekla Life Sciences Investors

Tekla Life Sciences Investors Fair Value Envelope

HQL · NYSE

Our analysis suggests that HQL has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $16.93, this represents a potential HIDDEN relative to our calculated worth for Tekla Life Sciences Investors.

Intrinsic Value
Current Price: $16.93